Antihypertensive therapy in octogenarians demonstrated significant mortality and morbidity benefits, and may lead to a reduction in incident cognitive impairment and fractures.
Does antihypertensive therapy reduce mortality, morbidity, cognitive impairment, and fractures in octogenarians with hypertension?
This review highlights that antihypertensive therapy in octogenarians provides significant mortality and morbidity benefits, and may also reduce cognitive impairment and fractures.
Early trials in the field of hypertension focused on adults in their fifties and sixties. However, with the passage of time, a progressive effort has been made to expand the evidence base for treatment in older adults. 2008 saw publication of data from the Hypertension in the Very Elderly Trial which demonstrated significant mortality and morbidity benefits from antihypertensive therapy in octogenarians. More recently, additional data from this cohort has been published suggesting that appropriate anti-hypertensive therapy may lead to a reduction in incident cognitive impairment and fractures, whilst a 1 year open label extension of the main study confirmed many of the original trial findings. This review provides an overview of the Hypertension in the Very Elderly Trial whilst also discursively evaluating the latest data.
Mukhtar et al. (Fri,) conducted a review in Hypertension. Antihypertensive therapy was evaluated on Mortality, morbidity, incident cognitive impairment, and fractures. Antihypertensive therapy in octogenarians demonstrated significant mortality and morbidity benefits, and may lead to a reduction in incident cognitive impairment and fractures.